Blase N. Polite

Blase Polite practices at Comer Children's Hospital - Hyde Park in Chicago, Illinois.

Blase Polite's NPI, 1306873211, was assigned on June 27, 2006. Blase Polite graduated from Indiana University School of Medicine in 2000. Blase Polite holds Illinois license 036108110.

Blase Polite's primary practice is Comer Children's Hospital - Hyde Park, at 5721 S Maryland Ave, Chicago, IL 60637 in Cook County. The practice phone is (773) 702-1530.

Blase Polite's primary practice is Comer Children's Hospital - Hyde Park in Chicago, Illinois. Blase Polite is also affiliated with University of Chicago Medical Center. The medical group on file is UChicago Medicine Physicians. Dmand AI also links Blase Polite to 1 more hospital and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Blase Polite practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Blase Polite's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Blase Polite is licensed in Illinois.

CMS data shows 287 Medicare services from Blase Polite across 6 procedure codes in 2024, for 144 Medicare patients. Medicare paid $23,516 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 144 Medicare patients who saw Blase Polite in 2024. The largest group is 65 to 74, with 72 patients. 71% of them have cancer, and 68% have high blood pressure. 22% are also on Medicaid. Their average risk score is 2.66, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Blase Polite's median patient age at 70, with 46% women.

In 2024, Blase Polite wrote 237 Medicare Part D claims for 49 patients. 91% of them were for generic drugs. CMS names the drug for 120 of them, across 8 drugs with 11 or more claims each, at $2,172 in total drug cost. In 2023, CMS named 196 claims across 9 drugs.

Blase Polite accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Blase Polite as offering telehealth.

Dmand AI links 124 papers to Blase Polite, published from 2008 to 2025. 2017 was the busiest year, with 12. The most frequent topics are Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Black or African American. Blase Polite has published most often in J Oncol Pract. Blase Polite's most frequent co-authors are Daniel V. Catenacci, Oliver S. Eng, MD and Ankit Dhiman.

Dmand AI links Blase Polite to 6 clinical trials, 2 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Anal Canal Carcinoma, Carcinoma, Merkel Cell and Colorectal Neoplasms, Hereditary Nonpolyposis. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 20 general payments to Blase Polite from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 56% of the total. Pfizer Inc. paid the most, $16,983.

Blase Polite graduated from Indiana University School of Medicine in 2000.